Raleigh Capital Management’s State Street SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF CERY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.89M Buy
116,452
+6,925
+6% +$250K 1.24% 14
2026
Q1
$3.86M Buy
109,527
+34,467
+46% +$1.11M 1.33% 11
2025
Q4
$2.14M Sell
75,060
-41,285
-35% -$1.21M 0.78% 38
2025
Q3
$3.33M Buy
116,345
+58,401
+101% +$1.63M 1.27% 14
2025
Q2
$1.58M Sell
57,944
-38,221
-40% -$1.03M 0.66% 47
2025
Q1
$2.66M Buy
96,165
+52,001
+118% +$1.41M 1.21% 13
2024
Q4
$1.14M Buy
+44,164
New +$1.15M 0.44% 68

Other funds holding CERY

Raleigh Capital Management's CERY Position: Q2 2026 in Review

Raleigh Capital Management increased its State Street SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF (CERY) stake by 6.3% in Q2 2026, buying an estimated $250K and bringing the position to 116,452 shares worth $3.89M. The position accounts for 1.24% of the portfolio, ranked #14.

Raleigh Capital Management first reported a position in CERY in Q4 2024 and has held it in 7 quarters since. 130 funds tracked by Wall St. Rank hold CERY as of Q2 2026.

  • Raleigh Capital Management held 116,452 shares of State Street SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF worth $3.89M as of Q2 2026.
  • Raleigh Capital Management bought 6,925 State Street SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF shares in Q2 2026, an estimated $250K.
  • State Street SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF made up 1.24% of Raleigh Capital Management's portfolio in Q2 2026, its #14 holding.
  • Raleigh Capital Management first reported a position in State Street SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF in Q4 2024 and has held it in 7 quarters since.
  • 130 funds tracked by Wall St. Rank held State Street SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.